OmniAb (OABI) Non-Current Deferred Tax Liability (2021 - 2026)
OmniAb (OABI) reported Non-Current Deferred Tax Liability of $1.2 million for Q1 2026, down 44.43% year-over-year from $2.2 million in Q1 2025, and up 56.31% quarter-over-quarter from $785000.0 in Q4 2025.
OmniAb (OABI) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $1.2 million in Q1 2026.
- Non-Current Deferred Tax Liability for Q1 2026 came in at $1.2 million, down 44.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 44.43% YoY), and the FY2025 annual result was $785000.0, down 97.78% from the prior year.
- Non-Current Deferred Tax Liability rose to $1.2 million in Q1 2026 per OABI's latest filing, from $785000.0 in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $35.4 million in Q4 2024 and troughed at $785000.0 in Q4 2025.
- A 5-year average of $10.5 million and a median of $7.8 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- The sharpest annual moves came in 2024 and 2025: Non-Current Deferred Tax Liability jumped 211.63% in 2024, then sank 97.78% in 2025.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $21.3 million in 2022, then tumbled by 46.8% to $11.4 million in 2023, then jumped by 211.63% to $35.4 million in 2024, then slumped by 97.78% to $785000.0 in 2025, then surged by 56.31% to $1.2 million in 2026.
- Business Quant data shows OABI's Non-Current Deferred Tax Liability at $1.2 million in Q1 2026, $785000.0 in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.23 Mn |
| Mar 31, 2026 | 1.23 Mn |
| Dec 31, 2025 | 785,000.00 |
| Dec 31, 2025 | 785,000.00 |
| Sep 30, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Dec 31, 2024 | 35.38 Mn |
| Dec 31, 2024 | 35.38 Mn |
| Sep 30, 2024 | 4.13 Mn |
| Sep 30, 2024 | 4.13 Mn |
| Jun 30, 2024 | 6.84 Mn |
| Jun 30, 2024 | 6.84 Mn |
| Mar 31, 2024 | 8.74 Mn |
| Mar 31, 2024 | 8.74 Mn |
| Dec 31, 2023 | 11.35 Mn |
| Dec 31, 2023 | 11.35 Mn |